Source - LSE Regulatory
RNS Number : 6869E
09 July 2021

9 July 2021


HeiQ Plc

("HeiQ" or "the Company")


Completion of Acquisition of Life Material Technologies Limited


HeiQ Plc (LSE: HEIQ), an established global brand in materials and textile innovation which operates in high-growth markets, announces that further to the RNS published on 15 June 2021, the acquisition of 100% of the share capital and voting rights of Life Material Technologies Limited ("HeiQ LIFE"), a materials technology company that has developed a strong portfolio of smart ingredients, has now completed (the "Acquisition").


The Acquisition strengthens HeiQ's presence in the bio-based antimicrobial and textile odor control market and further diversifies and innovates its product range and capabilities. HeiQ will initially focus on marketing HeiQ LIFE's bio-based, botanical antimicrobial technologies, which represent a sustainable solution for controlling odor on textiles, to apparel brands. Odor control is the highest in-demand apparel functionality amongst consumers worldwide and provides environmental benefits because odor-free garment requires less washing, leading to longer life and less water consumption.   


The Company will issue 1,887,883 new ordinary shares ("Consideration Shares") to the sellers of LIFE, at a price of £1.496201 per share, which is the intraday volume-weighted average price (the "VWAP") of HeiQ shares on the London Stock Exchange in the last five trading days preceding the closing of the Acquisition.


Applications will be made for the Consideration Shares to be admitted to the standard segment of the Official List, and to trading on the London Stock Exchange's Main Market ("Admission").


It is expected that Admission will become effective, and that dealings in the new Ordinary Shares are expected to commence, at 8.00 a.m. on 14 July 2021.


Following Admission, the total number of Ordinary Shares in issue will be 130,583,536 and the total number of voting rights will therefore be 130,583,536. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.




For further information, please contact:


HeiQ Plc

Carlo Centonze (CEO)

+41 56 250 68 50

Arlington Group Asset Management Limited (Financial Advisor and Joint Broker)

Charles Cannon Brookes

+44 (0) 207 389 5017

Cenkos Securities plc (Joint Broker)

Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

SEC Newgate (Media Enquiries)

Elisabeth Cowell / Robin Tozer / Megan Kovach

+44 (0) 20 3757 6882


About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. It is an IP-rich pioneer which is at the forefront of global technology in the $10 billion antimicrobial fabrics and $24 billion textile chemicals market. It has also moved into the medical device, healthcare and probiotics markets, to help make hospitals and healthcare environments more hygienic.

HeiQ has created some of the most effective, durable and high-performance technologies and textile effects in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands. It has won multiple awards and gained a strong reputation for sustainability.

Led by an experienced management team, HeiQ rapidly researches new solutions for partners, quickly delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A. It has a healthy R&D pipeline containing over 40 projects.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.